Rilapladib
Rilapladib is a lipoprotein-associated phospholipase A2 inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. It is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. Reference standards of Rilapladib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => Rilapladib - API
[catalogue_number] => PA 18 79000
[category_ids] => ,78,70,82,
[chemical_name] =>
[tag_name] =>
[weight] => 735.81
[form] => C40H38F5N3O3S
[cas] => 412950-08-4
[pslug] => 412950-08-4-rilapladib-api-pa1879000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 18 79000
Molecular Formula : C40H38F5N3O3S
Molecular Weight : 735.81
stdClass Object
(
[pname] => Rilapladib - API
[catalogue_number] => PA 18 1280000
[category_ids] => ,75,76,78,70,82,
[chemical_name] =>
[tag_name] =>
[weight] => 735.81
[form] => C40H38F5N3O3S
[cas] => 412950-08-4
[pslug] => 412950-08-4-rilapladib-api-pa181280000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 18 1280000
Molecular Formula : C40H38F5N3O3S
Molecular Weight : 735.81